摘要
为了弄清ＭＴｓ在乳腺癌过表达的生物学意义，我们应用免疫组化ＬＳＡＢ法对１０７例乳腺癌进行了检测。结果：８６例（８０．４％）乳腺癌有ＭＴｓ过表达，阳性物质位于癌细胞核内，或者同时位于细胞浆内。ＭＴｓ在浸润性乳腺癌中的表达与病理分级关系密切，Ⅱ级以上者阳性率明显高于Ⅰ级（Ｐ＜０．０５）；肿瘤最大直径小于２．５ｃｍ者ＭＴｓ表达率明显少于２．５ｃｍ以上者（Ｐ＜０．０５）；核分裂多者ＭＴｓ表达率明显高于核分裂少者（Ｐ＜０．０１）。ｃ－ｅｒｂＢ－２、ｐ５３、ｂｃ１－２癌蛋白和ｎｍ２３蛋白表达情况与ＭＴｓ过表达之间未见明显相关性。ＰＣＮＡ与ＭＴｓ过表达有关，ＰＣＮＡ指数在５０％以上者的ＭＴｓ表达率明显高于ＰＣＮＡ指数在５０％以下者（Ｐ＜０．０５）。有ＭＴｓ过表达的患者生存期明显短于无ＭＴｓ过表达者（Ｐ＜０．０５）。表明ＭＴｓ表达可作为预示乳腺癌进展快和预后差的生物学标志之一。
In order to study the biologic significance of metallothioneins (MTs) in breast cancer, 107 cases of breast cancer were studied immunohistochemically. MTs over expression was found in 86 cases of this series (80.4%). Positive staining for MTs was found in the nucleus or the cytoplasm of cancer cells or both.Intensity of expression of MTs in infiltrating breast cancer paralleled closely with the pathological grading of the tumor. The grading, the size of the tumor and the mitotic figures as well were correlated with the over expression of MTs.There was no association between the expressions of cerbB 2, p53, bcl, nm23 or that of MTs. The amount of PCNA however, correlated with the over expression of MTs. Patients with over expression of MTs was markedly shorter in survival than those without MTs expression. It is concluded that tumor tissue MTs expression can be taken as one of the biological markers predicting rapid progression and poor prognosis of the breast cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1998年第9期645-648,共4页
Chinese Journal of Clinical Oncology
基金
解放军医药卫生科研基金
